Photographic Library of Moderate to Severe Psoriasis Subjects Treated With Infliximab (Study P05047) (PHODYPSO)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Psoriasis

Treatments: Biological: Infliximab

Study type: Observational

Funder types: Industry

Identifiers

NCT00749398

P05047

Details and patient eligibility

About

This is a national, multi-center, observational, prospective photographic atlas study in subjects who are treated with infliximab for moderate-to-severe psoriasis in daily clinic according to local country regulations and reimbursement.

Full description

Subjects will enter this study using a non-probability sampling method.

Enrollment: 133 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female, age >=18 with moderate-to-severe psoriasis.
• Patient for whom the physician has decided to initiate psoriasis treatment with infliximab in accordance with the terms of the European labeling.
• Patient must demonstrate his/her willingness to participate in the observational study by signing a written consent.

Exclusion criteria

• Patient unable to understand and answer a self administered questionnaire.
• No specific non-inclusion criteria will be applied to eligible patients.
• Contradiction and/or Precaution listed in the Summary of Product Characteristics.

Trial design

133 participants in 1 patient group

Infliximab

Description:

Subjects with moderate-to-severe psoriasis who are treated with infliximab in daily clinics according to local country regulations and reimbursements.

Treatment:

Biological: Infliximab